Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 9 months from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(9 years from now) | |
US10888605 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(14 years from now) | |
US11752198 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(14 years from now) | |
US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(16 years from now) |
Wegovy is owned by Novo.
Wegovy contains Semaglutide.
Wegovy has a total of 6 drug patents out of which 0 drug patents have expired.
Wegovy was authorised for market use on 04 June, 2021.
Wegovy is available in solution;subcutaneous dosage forms.
Wegovy can be used as method for weight management according to a dose escalation schedule, method for weight management.
Drug patent challenges can be filed against Wegovy from 05 December, 2021.
The generics of Wegovy are possible to be released after 17 February, 2041.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jun 04, 2024 |
New Dosing Schedule(D-190) | Jul 21, 2026 |
New Indication(I-935) | Mar 08, 2027 |
New Patient Population(NPP) | Dec 23, 2025 |
New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
Drugs and Companies using
SEMAGLUTIDE ingredient